Last 24 quarters of trend data · Consumer Defensive · Household & Personal Products
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.83 | — | — | 16.08 | — | — | — | — | — | — | — | 82.38 | — |
| — | — | — | — | — | — | — | — | — | — | — | +6.6% | — | |
| P/S Ratio | 0.40 | 0.54 | 0.89 | 0.86 | 0.60 | 0.59 | 0.57 | 0.75 | 1.97 | 1.03 | 2.05 | 2.36 | 4.85 |
| — | -9.3% | +57.6% | +13.9% | -69.4% | -42.7% | -72.4% | -68.2% | -59.3% | -67.7% | -59.2% | -49.8% | -43.3% | |
| P/B Ratio | 2.07 | 2.90 | 3.85 | 3.62 | 3.64 | 3.82 | 2.99 | 3.94 | 10.13 | 6.74 | 8.89 | 6.86 | 11.33 |
| — | -24.1% | +28.6% | -8.1% | -64.1% | -43.4% | -66.4% | -42.6% | -10.5% | -10.5% | +28.5% | +23.9% | +50.1% | |
| P/FCF | 3.25 | 3.14 | 6.56 | 6.21 | 22.64 | 3.17 | 5.43 | 16.36 | — | — | 13.27 | 13.44 | — |
| — | -0.8% | +20.8% | -62.1% | — | — | -59.1% | +21.8% | — | — | — | — | — | |
| EV / EBITDA | 7412.86 | 14.69 | 47.02 | 40.05 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 403.93 | — | 4.73 | — | — | — | 53.30 | 130.20 | — | — | 71.35 | — |
| — | — | — | -91.1% | — | — | — | -25.3% | — | — | — | +45.9% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
The Beauty Health Company's operating margin was 0.2% in Q4 2025, up 9.1 pp QoQ and up 8.8 pp YoY. The trailing four-quarter average of -7.3% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.3% | 64.3% | 64.6% | 62.8% | 69.8% | 62.7% | 51.6% | 45.2% | 59.4% | 47.2% | -12.9% | 57.8% | 62.7% |
| — | +2.6% | +25.2% | +39.0% | +17.5% | +32.9% | +500.3% | -21.8% | -5.3% | -29.0% | -118.6% | -14.6% | -7.1% | |
| Operating Margin | -6.9% | 0.2% | -8.8% | -3.5% | -17.3% | -8.6% | -27.3% | -24.4% | -20.9% | -19.0% | -84.3% | -11.2% | -20.1% |
| — | +102.8% | +67.6% | +85.9% | +17.2% | +54.8% | +67.6% | -118.1% | -4.0% | -394.3% | -1619.2% | -130.5% | -8.0% | |
| Net Margin | -3.2% | -9.8% | -15.6% | 25.2% | -14.5% | -12.4% | -23.2% | 0.2% | -0.8% | -9.7% | -75.8% | 2.9% | -23.5% |
| — | +20.5% | +32.7% | +11205.6% | -1639.6% | -27.4% | +69.4% | -92.2% | +96.4% | -349.8% | -82990.4% | -53.1% | -156.3% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.8% | -12.8% | -15.8% | 32.8% | -20.6% | -18.5% | -28.4% | 0.3% | -1.1% | -12.6% | -58.6% | 2.2% | -12.9% |
| — | +31.0% | +44.3% | +10669.5% | -1764.0% | -47.1% | +51.6% | -86.0% | +91.4% | -801.3% | -221154.7% | +19.4% | -231.8% | |
| ROA | -1.6% | -1.6% | -2.2% | 3.3% | -1.5% | -1.5% | -2.6% | 0.0% | -0.1% | -1.0% | -7.5% | 0.3% | -2.0% |
| — | -8.3% | +15.8% | +12735.0% | -1838.9% | -50.8% | +65.2% | -92.3% | +96.2% | -373.1% | -106390.0% | -35.8% | -177.9% | |
| ROIC | -6.8% | 0.1% | -2.0% | -0.8% | -3.7% | -2.1% | -5.8% | -5.6% | -4.3% | -4.8% | -19.0% | -2.7% | -3.6% |
| — | +103.4% | +65.2% | +85.0% | +14.7% | +57.1% | +69.5% | -108.7% | -19.3% | -475.1% | -1662.5% | -82.5% | +35.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The Beauty Health Company's Debt/EBITDA ratio is 68.9x, down from 173.0x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 76.3% YoY to 1.66x, tightening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 6.20 | 6.20 | 5.77 | 5.09 | 12.32 | 10.97 | 9.52 | 8.20 | 10.80 | 12.67 | 8.36 | 4.65 | 5.10 |
| — | -43.5% | -39.3% | -37.9% | +14.1% | -13.4% | +13.8% | +76.6% | +112.0% | +181.5% | +187.7% | +118.3% | +133.1% | |
| Debt / EBITDA | 10519.44 | 68.85 | 172.97 | 139.48 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.66 | 1.66 | 4.98 | 5.15 | 7.47 | 7.00 | 6.56 | 6.49 | 6.57 | 6.07 | 5.86 | 9.28 | 10.35 |
| — | -76.3% | -24.1% | -20.7% | +13.7% | +15.3% | +11.9% | -30.0% | -36.5% | -44.4% | -49.8% | -18.9% | -27.4% | |
| Quick Ratio | 1.40 | 1.40 | 4.07 | 4.15 | 6.43 | 5.99 | 5.57 | 5.47 | 5.55 | 5.28 | 5.27 | 7.98 | 8.66 |
| — | -76.6% | -26.8% | -24.0% | +15.9% | +13.4% | +5.7% | -31.5% | -35.9% | -43.8% | -49.1% | -24.6% | -36.2% | |
| Interest Coverage | -1.08 | 0.03 | -0.69 | 5.52 | -2.68 | -3.76 | -5.62 | 0.94 | 0.56 | -1.62 | -19.42 | 1.34 | -6.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying SKIN stock.
The Beauty Health Company's current P/E is -5.8x. The average P/E over the last 1 quarters is 16.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
The Beauty Health Company's current operating margin is -6.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking The Beauty Health Company's business trajectory between earnings reports.